{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-061275","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.131433+00:00","generated_at":"2026-06-01T14:25:39.155369+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Cytokinetics director Smith resigns; stockholders approve 300K-share ESPP increase","bullets":["Sandford D. Smith resigned from the board effective before the 2024 annual meeting, not due to any disagreement.","Stockholders approved amendment to ESPP increasing authorized shares by 300,000 to total 1,159,879 shares.","Robert I. Blum and Robert A. Harrington elected as Class II directors for three-year terms.","Ernst & Young LLP ratified as independent auditor for 2024; say-on-pay proposal passed advisory vote.","Approximately 91.97% of eligible shares (96,181,650 votes) represented at the meeting, forming a quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-061275","json":"https://secwatch.observer/filing/0000950170-24-061275.json","markdown":"https://secwatch.observer/filing/0000950170-24-061275.md","text":"https://secwatch.observer/filing/0000950170-24-061275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/cytk-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T14:25:39.155369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50c4892c53","claim":"Sandford D. Smith resigned as Director at CYTOKINETICS INC.","evidence_excerpt":"On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","confidence":0.95},{"claim_id":"23a54c37e0fc9223e2d8f4b0385ea972256260f0","claim":"CYTOKINETICS INC shareholders approved Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock..","evidence_excerpt":"Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","confidence":0.9},{"claim_id":"71bd5ff0eeb9ed6369f5b0c61ccb56de1c471bab","claim":"CYTOKINETICS INC shareholders approved Election of Two Class II Directors.","evidence_excerpt":"Proposal 1: Election of Two Class II Directors The stockholders elected Robert I. Blum and Robert A. Harrington, M.D. as Class II Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal. The voting for each director was as follows: Name For Withheld Broker Robert I. Blum 87,317,169 2,214,926 6,649,555 Robert A. Harrington, M.D. 78,347,186 11,184,909 6,649,555","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","confidence":0.9},{"claim_id":"a3fa0bcb4a7f6d274bbba30f3db55ecc3ab03866","claim":"CYTOKINETICS INC shareholders approved Advisory Vote on Executive Compensation.","evidence_excerpt":"Proposal 4: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the 2024 Proxy Statement. The votes were as follows: For Against Abstain Broker Non-Vote 85,814,395 2,927,007 790,693 6,649,555","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","confidence":0.9},{"claim_id":"bb55d5420a0729e224349745cd2407a903645761","claim":"CYTOKINETICS INC shareholders approved Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 at the 2024-12-31 meeting.","evidence_excerpt":"Proposal 3: Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 The stockholders ratified the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were as follows: For Against Abstain 95,957,265 97,750 126,635","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001636282-26-000056","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-05-29T20:45:58+00:00","headline":"Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000056","json":"https://secwatch.observer/filing/0001636282-26-000056.json","markdown":"https://secwatch.observer/filing/0001636282-26-000056.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/0001636282-26-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/syre-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","comparable_excerpt":"In addition, effective as of May 27, 2026, Peter Harwin resigned from the Board.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/0001636282-26-000056-index.htm"}},{"accession":"0001193125-26-251659","ticker":"MPT","company_name":"MEDICAL PROPERTIES TRUST INC","filed_at":"2026-06-01T20:55:09+00:00","headline":"MPT shareholders elect all directors, approve say-on-pay and equity plan with notable opposition","event_type":"other_material","sec_items":["5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251659","json":"https://secwatch.observer/filing/0001193125-26-251659.json","markdown":"https://secwatch.observer/filing/0001193125-26-251659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287865/000119312526251659/0001193125-26-251659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287865/000119312526251659/mpt-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","comparable_excerpt":"Proposal 2: The ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026: For: Against: Abstensions: Broker Non-Votes: 459,883,831 6,189,396 2,613,330 —","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1287865/000119312526251659/0001193125-26-251659-index.htm"}},{"accession":"0001437749-26-019042","ticker":"LODE","company_name":"Comstock Inc.","filed_at":"2026-06-01T20:15:18+00:00","headline":"Comstock holds AGM; all director nominees elected, auditor and equity plan approved","event_type":"other_material","sec_items":["5.07","7.01","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.25,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-019042","json":"https://secwatch.observer/filing/0001437749-26-019042.json","markdown":"https://secwatch.observer/filing/0001437749-26-019042.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1120970/000143774926019042/0001437749-26-019042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1120970/000143774926019042/lode20260513_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","comparable_excerpt":"4. Vote on Comstock Inc. 2026 Equity Incentive Plan. The stockholders approved the Comstock Inc. 2026 Equity Incentive Plan as set forth below. Voted For Voted Against Abstain Broker Non-Votes 25,069,375 1,393,479 1,194,028 21,410,649","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1120970/000143774926019042/0001437749-26-019042-index.htm"}},{"accession":"0001104659-26-068886","ticker":"HNVR","company_name":"Hanover Bancorp, Inc. /MD","filed_at":"2026-06-01T20:00:16+00:00","headline":"Shareholders elect three directors, approve equity plan, ratify auditor at annual meeting","event_type":"other_material","sec_items":["5.02","5.07"],"materiality_score":0.25,"calibrated_materiality_score":0.25,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068886","json":"https://secwatch.observer/filing/0001104659-26-068886.json","markdown":"https://secwatch.observer/filing/0001104659-26-068886.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828588/000110465926068886/0001104659-26-068886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828588/000110465926068886/hnvr-20260528x8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","comparable_excerpt":"2. The Hanover Bancorp, Inc. 2026 Equity Incentive Plan was approved by the shareholders by the following vote: ​ FOR AGAINST ABSTAIN 4,755,228 27,522 43,684 ​ ​ There were 903,723 broker non-votes on the proposal.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1828588/000110465926068886/0001104659-26-068886-index.htm"}},{"accession":"0001628280-26-039572","ticker":"VOYG","company_name":"Voyager Technologies, Inc./DE","filed_at":"2026-06-01T20:49:39+00:00","headline":"Stockholders approve redomestication from Delaware to Texas at annual meeting","event_type":"other_material","sec_items":["5.07"],"materiality_score":0.55,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039572","json":"https://secwatch.observer/filing/0001628280-26-039572.json","markdown":"https://secwatch.observer/filing/0001628280-26-039572.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788060/000162828026039572/0001628280-26-039572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788060/000162828026039572/voyg-20260529.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","comparable_excerpt":"The results of the vote were as follows: For Against Abstain Broker Non-Votes 98,600,810 8,426,781 98,301 13,043,864 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1788060/000162828026039572/0001628280-26-039572-index.htm"}},{"accession":"0001579684-26-000040","ticker":"TDAY","company_name":"USA TODAY Co., Inc.","filed_at":"2026-06-01T20:31:33+00:00","headline":"Annual meeting elects directors, ratifies auditor; four governance proposals fail to meet 80% supermajority threshold","event_type":"other_material","sec_items":["5.07"],"materiality_score":0.4,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001579684-26-000040","json":"https://secwatch.observer/filing/0001579684-26-000040.json","markdown":"https://secwatch.observer/filing/0001579684-26-000040.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579684/000157968426000040/0001579684-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579684/000157968426000040/tday-20260601.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","comparable_excerpt":"Proposal 1 . The Company's stockholders elected the following eight director nominees to serve until the 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1579684/000157968426000040/0001579684-26-000040-index.htm"}},{"accession":"0001437749-26-019044","ticker":"NSTS","company_name":"NSTS Bancorp, Inc.","filed_at":"2026-06-01T20:16:05+00:00","headline":"NSTS Bancorp annual meeting: directors elected, auditor ratified","event_type":"other_material","sec_items":["5.07"],"materiality_score":0.1,"calibrated_materiality_score":0.1,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-019044","json":"https://secwatch.observer/filing/0001437749-26-019044.json","markdown":"https://secwatch.observer/filing/0001437749-26-019044.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1881592/000143774926019044/0001437749-26-019044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1881592/000143774926019044/nsts20260527_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","comparable_excerpt":"The ratification of the appointment of Plante & Moran, PLLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026: FOR AGAINST ABSTAIN BROKER NON-VOTES 3,708,805 207,145 85,662 0","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1881592/000143774926019044/0001437749-26-019044-index.htm"}},{"accession":"0001419536-26-000103","ticker":"CBNK","company_name":"Capital Bancorp Inc","filed_at":"2026-06-01T20:05:37+00:00","headline":"Capital Bancorp shareholders elect all director nominees, approve say-on-pay, ratify auditor","event_type":"other_material","sec_items":["5.07"],"materiality_score":0.15,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001419536-26-000103","json":"https://secwatch.observer/filing/0001419536-26-000103.json","markdown":"https://secwatch.observer/filing/0001419536-26-000103.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419536/000141953626000103/0001419536-26-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419536/000141953626000103/cbnk-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024061275/0000950170-24-061275-index.htm","comparable_excerpt":"Proposal 3 – The ratification of the appointment of Elliott Davis, PLLC as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026. FOR AGAINST ABSTAIN BROKER NON-VOTES 13,466,844 198,796 9,223 0","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1419536/000141953626000103/0001419536-26-000103-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}